ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 534

Increased Insulin Resistance and Impaired Beta-Cell Function in Patients with Rheumatoid Arthritis: The Role of Glucocorticoid Therapy?

Gorica Ristic1, Vesna Subota2, Dejana Stanisavljevic3, Branislava Glisic1, Milan Petronijevic1 and Dusan Stefanovic1, 1Department of Rheumatology and Clinical Immunology, Military Medical Academy, Belgrade, Serbia, 2Institute of Medical Biochemistry, Military Medical Academy, Belgrade, Serbia, 3Institute of Medical Statistics, Belgrade University School of Medicine, Belgrade, Serbia

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: B cells, glucocorticoids, insulin resistance and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Increased insulin resistance and impaired β-cell function have been demonstrated in rheumatoid arthritis (RA). The aim of the study was to analyze the association of these metabolic disturbances with glucocorticoid (GC) therapy.

Methods: The study population included 127 non-diabetic subjects: 90 RA pts (mean age 52.4±9.9 yrs, disease duration 9 yrs, range 4-13) and 37 matched controls (mean age 49.0±7.5 yrs). All pts were on disease modifying anti-rheumatic drugs (methotrexate in 93.3%), biologic therapy in 27.8%, and GC in 65.6%, none on GC>10 mg/day (median dose 5 mg/day, range 5-10, during 4 yrs (range 2-6 yrs), cumulative GC dose was 9.1 g (5.5-16.4 g). Clinical work-up included determination of the body mass index (BMI), waist circumference (WC), blood pressure (BP), disease activity (mDAS28-SE), inflammation markers, lipids, glucose, specific insulin, and C peptide. The updated-computer Homeostasis Model Assessment was used to calculate insulin resistance (HOMA2-IR) and β-cell function (HOMA2-%B). HOMA2-IR>1 was defined as increased insulin resistance. Lack of compensatory rise of HOMA2-%B implied impaired β-cell function.

Results: Increased insulin resistance (logHOMA2-IR>1) was detected in 74.4% of RA pts and in 54.2% of controls, p=0.025. RA pts had also higher values of logHOMA2-IR than controls 1.4 (range 1.0-2.3) vs. 1.2 (range 0.8-1.4); p=0.008; which was followed with impaired β cell function: HOMA2-%B 148 (116-190) vs.141 (114-158) p=0.186. Univariate regression revealed association of logHOMA2-IR with all insulin resistance risk factors: age, BMI, WC, BP, and triglycerides, while multivariate analysis demonstrated that beside BMI, and triglycerides, daily dose of GC was an independent risk factor for logHOMA2-IR (β 0.191, 95% CI 0.020-0.361, p=0.029).  On the other hand, statistical difference was not found for duration of GC therapy and cumulative GC dose. Analyzing patients with and without GC therapy statistical difference was not found regarding any parameters of glucose metabolism, as well as all classic insulin resistance risk factors (Table 1). In comparison with controls, higher insulin resistance was found for RA pts with GC therapy, which was not followed with differences in B cell function. Patients without GC therapy also had higher insulin resistance, but the statistical significance was borderline. Both RA groups had significantly higher number of subjects with increased insulin resistance than controls.

Conclusion: There was no significant difference in insulin resistance between RA pts with and without GC therapy. Daily dose has more significant influence than duration of GC therapy and cumulative GC dose but this therapy does not play a principal role in increased insulin resistance in RA pts.


Disclosure: G. Ristic, None; V. Subota, None; D. Stanisavljevic, None; B. Glisic, None; M. Petronijevic, None; D. Stefanovic, None.

To cite this abstract in AMA style:

Ristic G, Subota V, Stanisavljevic D, Glisic B, Petronijevic M, Stefanovic D. Increased Insulin Resistance and Impaired Beta-Cell Function in Patients with Rheumatoid Arthritis: The Role of Glucocorticoid Therapy? [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/increased-insulin-resistance-and-impaired-beta-cell-function-in-patients-with-rheumatoid-arthritis-the-role-of-glucocorticoid-therapy/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-insulin-resistance-and-impaired-beta-cell-function-in-patients-with-rheumatoid-arthritis-the-role-of-glucocorticoid-therapy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology